In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Journey Medical Corp.

https://journeymedicalcorp.com/

Latest From Journey Medical Corp.

Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy

Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.

Deal Watch Business Strategies

A Standard September Ahead Thanks To Light US FDA User Fee Calendar With Few Expedited Reviews

Twelve applications with September goal dates include six novel agents but only one breakthrough designation.

US FDA Performance Tracker Approvals

Don’t Stop Relieving: Journey’s DFD-29 Trounces Oracea In Reducing Rosacea Lesions

The company posted positive topline results from the Phase III MVOR-1 and MVOR-2 trials comparing DFD-29 against Galderma’s drug in papulopustular rosacea.

Clinical Trials Dermatology

Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Growth Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register